Esperion Therapeutics Inc (ESPR) 104.60 $ESPR Open

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 1:13 PM

Esperion Therapeutics Inc (ESPR) 104.60 $ESPR

Open Minded about Closed Offerings
M2 - Tue Apr 21, 8:44AM CDT
Considering that not long ago shareholders would run away the moment that a company announced a secondary offering, it's great to see that the greater investing public is often embracing this key expansionary tool. The standard operating procedure was to employ a static valuation model, based on the dilution compared to the company's current earnings. However, many investors are now also factoring in the company's reasonable future earnings potential into the equity valuation model.
ESPR: 104.60 (-4.29), CACC: 216.38 (+5.39), FISI: 23.73 (-0.44), BXMT: 31.27 (+0.06), VLTC: 11.54 (+0.50)

Critical Alerts For BlackBerry, Hasbro, Esperion Therapeutics, Chesapeake Energy and OmniVision Released By InvestorsObserver
PR Newswire - Tue Apr 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BBRY, HAS, ESPR, CHK and OVTI.
HAS: 71.61 (-0.10), ESPR: 104.60 (-4.29), CHK: 14.54 (unch), BBRY: 10.38 (+0.11), OVTI: 26.62 (-0.19)

3 Biotech Stocks That Could Be Developing Billion Dollar Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 19, 10:07AM CDT
Billion dollar blockbuster status is the Holy Grail pursued by every drugmaker, but developing blockbuster drugs isn't easy. According to the Tufts Center for the Study of Drug Development, it costs $1.4 billion to develop and commercialize a new...
BIIB: 401.71 (-28.57), ESPR: 104.60 (-4.29), GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), RCPT: 169.88 (-1.26)

3 Top Healthcare Stocks Surging Higher This Year
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 11:03AM CDT
Aging baby boomers and an increasingly insured population are driving healthcare utilization higher, and that has made stocks in this industry some of the market's best performers over the past three years. A number of healthcare stocks are soaring...
ESPR: 104.60 (-4.29), AZN: 71.79 (-1.34), HZNP: 31.75 (+0.97), TEVA: 64.41 (+1.16), EGRX: 59.30 (-1.62), HPTX: 45.97 (-0.11)

The 3 Best Stocks for Investing in Cholesterol Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 10:04AM CDT
Statins' cholesterol-lowering ability and a growing global need for cholesterol-busting treatment have turned statins into some of the most widely-prescribed drugs in the world. But until recently, investors hoping to profit from the billions of...
ESPR: 104.60 (-4.29), AMGN: 167.91 (-1.26), SNY: 51.75 (-0.01), REGN: 480.09 (+0.01)

Big Pharmas' Dirty Little Secret About Cholesterol Lowering Drugs
Mark Chapman - at Seeking Alpha - Wed Apr 15, 10:19AM CDT

ESPR: 104.60 (-4.29), ALNY: 119.01 (+0.29), MDCO: 27.41 (+0.09), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), AMGN: 167.91 (-1.26), LLY: 71.58 (-0.82), SNY: 51.75 (-0.01), REGN: 480.09 (+0.01)

Esperion Therapeutics to Present at 14th Annual Needham Healthcare Conference
Marketwired - Tue Apr 07, 3:30PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that president and chief executive officer, Tim M. Mayleben, will present at the 14th Annual Needham Healthcare Conference in New York City on Tuesday, April 14, 2015 at 1:40 p.m. Eastern Time.
ESPR: 104.60 (-4.29)

Healthcare ratings round up
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 12:23PM CDT

OXGN: 1.48 (unch), TRVN: 6.69 (-0.30), ESPR: 104.60 (-4.29), OVAS: 30.40 (-0.55), UHS: 122.69 (+0.09), NLNK: 52.10 (-0.90), RTRX: 24.75 (+0.01), SYK: 96.90 (-0.28)

Here's How Esperion Therapeutics, Inc. Could Get to $140
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 01, 4:27PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Esperion Therapeutics , a clinical-stage...
ESPR: 104.60 (-4.29)

Esperion Up As UBS Touts Cholesterol Drug
at Investor's Business Daily - Wed Apr 01, 2:44PM CDT
Shares of development-stage pharmaceutical firm Esperion Therapeutics (ESPR) jumped 11% Wednesday after UBS initiated coverage of Esperion stock with a buy rating, praising its cholesterol drug candidate. Analyst Andrew Peters wrote that ETC-1002, a...
ESPR: 104.60 (-4.29), MRK: 57.60 (+0.09), AMGN: 167.91 (-1.26), SNY: 51.75 (-0.01), REGN: 480.09 (+0.01)

The Top-Performing Biotech Stock During a Sizzling First Quarter
at The Street - Wed Apr 01, 8:30AM CDT
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
CRMD: 8.61 (-0.22), BIIB: 401.71 (-28.57), ESPR: 104.60 (-4.29), FMI: 46.57 (-2.16), ANTH: 5.20 (+0.31), XBI: 233.86 (-2.86), IBB: 363.70 (-3.98), TRIL: 24.21 (+2.05)

Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Mar 30, 12:43PM CDT
The investment bankers were busy this weekend with four healthcare industry acquisitions announced today. Teva Pharmaceuticals is buying Auspex Pharmaceuticals for $3.5 billion, Horizon Pharma picked up Hyperion Therapeutics for $1.1 billion,...
ESRX: 87.34 (+0.45), CTRX: 59.56 (+0.05), ESPR: 104.60 (-4.29), ACAD: 38.36 (-0.54), BMRN: 120.28 (-2.67), ICEL: 16.48 (-0.02), UNH: 118.69 (+0.43), HZNP: 31.75 (+0.97), TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01), ABBV: 66.07 (+1.82), HPTX: 45.97 (-0.11)

3 Little-Known Biotechs Working On Potential Blockbusters
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 12:08PM CDT
Biotech stocks are prone to jaw-dropping pops and drops, caused by even the hint of positive or negative news surrounding drugs in their pipelines. That makes biotech one of the riskiest industries for investors. However, for those willing to take on...
ESPR: 104.60 (-4.29), PFE: 35.27 (-0.09), OPHT: 52.15 (+0.17), PRTA: 37.35 (-0.48), REGN: 480.09 (+0.01), NVS: 104.28 (-1.22)

First Week of May 15th Options Trading For Esperion Therapeutics (ESPR)
DividendChannel.com - Fri Mar 27, 9:53AM CDT
Investors in Esperion Therapeutics Inc saw new options begin trading this week, for the May 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ESPR options chain for the new May 15th contracts and...
ESPR: 104.60 (-4.29)

3 Biotech Stocks That Dropped Yesterday -- Is 1 a Buy?
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 26, 7:31AM CDT
The biotech stock bubble got a bit deflated this week as the biotech industry ETF tumbled more than 4% on Wednesday. The drop-off in share prices was widespread across the industry, but some stocks were punished more than others. Among those that...
ZIOP: 10.81 (-0.39), ESPR: 104.60 (-4.29), NVAX: 8.58 (-0.07), PFE: 35.27 (-0.09), XON: 44.10 (-0.91)

Why Esperion Therapeutics, Inc. Shares Burst Today.
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 25, 12:16PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Esperion Therapeutics ...
ESPR: 104.60 (-4.29)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 11:45AM CDT

TANH: 12.29 (+0.54), CCSC: 5.42 (-0.15), STMP: 66.23 (-0.77), HGSH: 3.28 (+0.05), FSNN: 4.24 (-0.18), ATRA: 59.89 (-4.13), KRFT: 87.57 (-0.81), LPTN: 2.23 (-0.01), IIJI: 8.39 (-0.15), KFX: 11.02 (-0.01), ESPR: 104.60 (-4.29), FCSC: 3.87 (+0.12), ORMP: 7.45 (+0.08), AFMD: 11.72 (+3.47), SEED: 1.77 (+0.16), CALA: 13.41 (-0.35), LIME: 2.83 (-0.06), VBLT: 4.23 (+0.07), APOL: 17.51 (-0.40), REPH: 11.88 (+1.04)

Weakness Seen in Esperion Therapeutics (ESPR): Stock Tumbles 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 7:39AM CDT
Make sure to keep an eye on Esperion Therapeutics going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
ESPR: 104.60 (-4.29)

Esperion closes equity offering
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 3:58PM CDT

ESPR: 104.60 (-4.29)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tech Job Market Surges with AI and IT Skills Spike

Alright, folks, though we're not drowning in champagne just yet, there's a promising uptick in October's tech employment, signaling a rebound or at least some relief for tech pros and market watchers. CompTIA's numbers show a boost of 7,200 jobs in the tech industry while IT occupations expanded by 26,000 slots. That's no small feat when the general job scene elsewhere...

Pepsi Drivers in Georgia Gear Up for a Strike Showdown

Teamsters Turn Up the Heat in Georgia Well, folks, buckle up because we've got ourselves a brewing labor storm down in Georgia! Over 100 Pepsi-Cola drivers, holding the steering wheel firm under Teamsters Local 528, are about ready to slam their fists down and go on strike. They've had it up to here with management's tap-dancing around negotiations. Drivers Say Enough Is...

IBM's Quantum Leap in Chicago Puts Illinois on Map

Chicago Steps into the Quantum Race In a world where cutting-edge tech isn't just desired, it's demanded, Chicago's just put itself on the quantum map with IBM's latest move. The unveiling of IBM Quantum System Two at the University of Chicago marks a milestone not just for the city, but for Illinois at large. This isn't some pie-in-the-sky tech dream—it's a tangible...

West Virginia Water Gains: Central Grove Upgrade Begins

Kickoff at Central Grove: What’s Brewing? Ever wander through Kearneysville, W.Va., and wonder what’s going on with that bustling crew near Goldenrod Drive? The folks at West Virginia American Water have kicked off groundwork for the much-anticipated Central Grove Water Treatment Plant. This, comrades, isn’t just some shiny new shed we’re talking about. Oh no,...

Innodisk's Q3 Revenue Surges 579.9% Boosting AI Growth

Innodisk's Skyrocketing Financial Surge Imagine raking in a revenue leap of 579.9% year-over-year. Yep, that's what Innodisk—a major player from Taiwan in industrial memory, storage, and edge AI solutions—just reported for Q3. I'll go out on a limb here and say that doesn't happen every day. Key Numbers That Paint the Big Picture Let’s dive into those digits. We're...

Sass Magazine's 2026 COZY Issue Embraces Intentional Joy

An Unexpected Shift in Sass's Seasonal Focus When you think November and December, it's easy to picture the hustle and bustle of holiday preparations—shopping, parties, running around. But toss all that hullabaloo out the window, because Sass Magazine has thrown a curveball for their 2026 release. They're steering the ship towards the calm, with their COZY Issue shaping...

Pen Needles Market to Hit $3.37B by 2031: Growth Ahead

Big Numbers in the Needle Game When you're staring down the numbers popping out of this pen needles market projection, it's hard to ignore—shooting from a respectable $2.16 billion in 2026 to a hefty $3.37 billion by 2031. We're talking a 9.3% CAGR that'll have investors pulling out their calculators or maybe rubbing their hands in downright glee, depending on their...

Elanco Surges with Solid Q3, Raises 2026 Forecast

Strong Q3 Performance Ignites Elanco's Growth Now here's a headline: Elanco's numbers are charging like a bull on steroids. Revenue surged 11% year-over-year to hit a cool $1.265 billion, showing off a 9% organic constant currency growth. And why should we, the investors, care? Because they've adjusted their EBITDA margin upwards to 19.5%, an impressive 2% boost from the...

Illinois Greenlights Major Water Utility Merger

Regulators Signal Green Light for Major Merger When was the last time a deal didn't hit some bumps in the regulatory road? This time, American Water and Essential Utilities are keeping the wheels greased, with the Illinois Commerce Commission giving their merger proposal a thumbs up. It feels like a classic case of utilities sticking to their market playbook—get bigger...

Kestrel Group Faces Financial Hit Despite Revenue Growth

Kestrel's Financial Rollercoaster Continues Here's the deal with Kestrel Group, folks. They just dropped their Q3 2026 financials, and it's a mixed bag. The top line's looking solid with total revenues hitting $4.8 million, riding high on a 203% jump in Program Services fee income. But dig a little deeper, and there's a $16.4 million net loss staring us in the face....